Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 9/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.61 |
| ▸ | PIM1 | P11309 | 7/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400690 | 0.93 | NTRK1 (0.55) | PIM3PIM2PIM1NTRK1IRAK4 | |
| SCHEMBL406175 | 0.93 | NTRK1 (0.55) | PIM3PIM2PIM1NTRK1IRAK4 | |
| SCHEMBL402153 | 0.89 | NTRK1 (0.62) | PIM3PIM2PIM1NTRK1IRAK4 | |
| SCHEMBL401794 | 0.84 | NTRK1 (0.49) | PIM3PIM2PIM1NTRK1IRAK4 | |
| SCHEMBL405870 | 0.84 | NTRK1 (0.56) | NTRK1IRAK4JAK2JAK1TYK2 | |
| SCHEMBL405249 | 0.84 | IRAK4 (0.57) | NTRK1IRAK4JAK2JAK1TYK2 | |
| SCHEMBL17387396 | 0.83 | PIM2 (0.68) | PIM3PIM2PIM1IRAK4RET | |
| SCHEMBL404768 | 0.82 | LMNA (0.53) | NTRK1IRAK4JAK2JAK1TYK2 | |
| SCHEMBL405725 | 0.82 | NTRK1 (0.54) | NTRK1IRAK4JAK2JAK1TYK2 | |
| SCHEMBL406028 | 0.81 | IRAK4 (0.70) | NTRK1IRAK4JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PIM3 291/4885PIM2 114/4885PIM1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.